Ionetix Gains First ANDA Approval for Ga-68 Gozetotide, Expanding Multi-Site PET Network

The first commercial ANDA approval for Gallium Ga-68 gozetotide (PSMA-11) lands with Ionetix Corporation, a development that sharpens the regulatory and manufacturing calculus for any facility operating in the short-lived radiopharmaceutical space. The FDA cleared the application on 26 May 2026, making Ionetix the first commercial drug manufacturer to hold this approval for the PSMA-targeted PET diagnostic agent.

The product's logistics profile is unforgiving: supplied as a single-dose capped syringe of approximately 8 to 10 mL, it carries a three-hour expiration from end of synthesis. That constraint makes geographic distribution architecture a direct GMP concern, not merely a commercial one. Ionetix has indicated it intends to leverage its existing multi-site cyclotron network to reach underserved markets, a strategy that places cyclotron uptime, batch release timelines, and inter-site quality system alignment under immediate operational scrutiny.

For QA directors and regulatory leads, the ANDA pathway itself carries weight here. Radiopharmaceuticals approved via ANDA must demonstrate bioequivalence and conform to 21 CFR Part 211 current GMP requirements, alongside the specific compendial and labeling standards tied to the reference listed drug. Ionetix's approval signals that the FDA is prepared to process ANDA submissions for this class of short-shelf-life PET agents, a precedent that could accelerate competitive filings and raise the bar on process validation documentation across the sector.

Gallium Ga-68 gozetotide is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer who present with suspected metastasis as candidates for initial definitive therapy, or with suspected recurrence based on elevated serum PSA. The clinical indication is well-established; the manufacturing and regulatory infrastructure to support broad commercial supply at this half-life is not. Ionetix's superconducting cyclotron technology underpins its production model, and the company is already generating revenue across PET diagnostics and alpha emitter therapeutics, including Actinium-225 and Astatine-211 for targeted alpha therapy programs.

Jill Wilson, Vice President of Regulatory Affairs and Quality Assurance at Ionetix, noted the approval enables dose supply to underserved areas through the company's existing facility network, a statement that points directly to the distribution and sterility assurance challenges inherent in scaling a product with a three-hour usable window.

The measurable checkpoint ahead is whether Ionetix's multi-site network can sustain consistent batch release and cold-chain integrity at commercial volumes within that synthesis-to-expiry constraint.

Source: Ionetix Corporation via GlobeNewswire, 26 May 2026.